camrelizumab + bevacizumab

A combination therapy consisting of camrelizumab, an anti-PD-1 monoclonal antibody, and bevacizumab, an anti-VEGF monoclonal antibody. Camrelizumab enhances T-cell immune responses against cancer cells by blocking the PD-1 pathway, while bevacizumab prevents the growth of new blood vessels that tumors need to grow by targeting VEGF. This dual approach aims to simultaneously activate the immune system against cancer cells while cutting off the tumor's blood supply.

Brand names

AiRuiKaAvastin

Other names

PD-1 inhibitor + bevacizumabC-Women's Hospital School Of Medicine Zhejiang University-gestational trophoblastic neoplasia